Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

87.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
 
Via Benzinga
A Closer Look at Merck & Co's Options Market Dynamics
 
Via Benzinga
Forecasting The Future: 12 Analyst Projections For Merck & Co
 
Via Benzinga
Why Merck (MRK) Stock Is Falling Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by a... 
Via StockStory
Gapping S&P500 stocks in Tuesday's session
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Get insights into the top movers in the S&P500 index of Tuesday's pre-market session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
Merck Tops Q4 Earnings And Revenue Estimates
Merck came out with quarterly earnings of $1.72 per share. 
Via Talk Markets
Topics Stocks / Equities
Balancing Dividends and Fundamentals: The Case of NYSE:MRK.
Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics. 
Via Chartmill
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
Via The Motley Fool
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact. 
Via Benzinga
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s... 
Via StockStory
Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 Guidance
Merck topped Wall Street's Q4 expectations Tuesday, but the stock is taking a hit on light guidance. 
Via Investor's Business Daily
Topics Stocks
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Earnings Scheduled For February 4, 2025
 
Via Benzinga
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is... 
Via Benzinga
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
5 Top Stocks to Buy in February 2025
All of them have great upside. 
Via The Motley Fool
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
From Merck & Co., Inc.
Via Business Wire
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
From Merck & Co., Inc.
Via Business Wire
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr. 
Via Investor's Business Daily
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
From Merck & Co., Inc.
Via Business Wire
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment. 
Via Benzinga
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.